Britain moves closer to Covid-19 vaccine trials that infect volunteers

If agreed, this would involve creating a human challenge study model that could be used should such trials gain ethical and safety approval from regulators

UK Covid
Supporters of human challenge trials say they are a good way to cut short the often lengthy process of testing potential vaccines
Kate Kelland | Reuters London
2 min read Last Updated : Oct 17 2020 | 1:06 AM IST
“Human challenge” trials of potential Covid-19 vaccines, where volunteers are deliberately infected with the disease, could become a reality after a British biotech firm said it was in advanced talks with the government to create and provide strains of the virus.
 
Preliminary work for the trials, which aim to speed up the process of determining the efficacy of a vaccine candidate, is being carried out by hVIVO, a unit of pharmaceutical services group Open Orphan, the company said. “We are in discussions with numerous parties including the UK government around a Covid-19 challenge study, and once any of those contracts are signed we will make an announcement,” said Cathal Friel, Open Orphan’s executive chairman.
 
If agreed, this would involve creating a human challenge study model that could be used should such trials gain ethical and safety approval from regulators.
 
Supporters of human challenge trials say they are a good way to cut short the often lengthy process of testing potential vaccines on tens of thousands of volunteers in the real world who go about normal life and are monitored to see if they contract the disease or are protected from it.
 
In these tightly-controlled trials, volunteers are given a vaccine and then about a month later are deliberately infected with the disease under controlled conditions. They are then isolated in a quarantine facility and monitored to see if they become sick or if the vaccine protects them.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineBritain

Next Story